According to the current analysis of Emergen Research, the global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 4.67 billion by 2027, at a CAGR of 14.4%.
According to the current analysis of Emergen Research, the global Transcatheter Mitral Valve Implantation Market was valued at USD 1.82 billion in 2019 and is expected to reach USD 4.67 billion by 2027, at a CAGR of 14.4%. The Transcatheter Mitral Valve Implantation market is growing at a significant rate owing to the technological advancements in transcatheter mitral valve implantation devices, and the rising prevalence of mitral valve diseases. Mitral valve disease is one of the most common valvular diseases, which occurs when the leaflets of the mitral valve do not close properly. When the leaflets do not close properly, blood flows in the wrong direction through the valve, which is known as regurgitation. This can lead to symptoms such as fatigue, shortness of breath, and heart palpitations.
Transcatheter mitral valve implantation (TMVI) is a minimally invasive surgical procedure used to treat mitral valve disease. In this procedure, a catheter is inserted through a small incision in the chest and threaded through the blood vessels to the heart. The transcatheter mitral valve is then implanted in the patient’s native mitral valve.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/54
A practicable and comparatively safe option to surgical valve repair or replacement, transcatheter mitral valve implantation (TMVI) is an interventional cardiology procedure used to treat patients with severe mitral valve insufficiency who are not candidates for surgery or who are at a high risk for death during surgery. In recent years, the use of TMVI has grown exponentially due to technological advancements in transcatheter valve devices and procedural techniques.TMVI is a less invasive alternative to surgical valve repair or replacement and is associated with shorter hospital stays, fewer complications, and faster Recovery times.
Further key findings from the report suggest
- In March 2019, MitraClip’s label was expanded by the U.S. FDA to include treatment of secondary mitral valve regurgitation (MR) in patients who have symptomatic heart failure and are not candidates for surgical valve repair. The expansion of the label was based on data from the COAPT trial, which enrolled 1,050 subjects with symptomatic refractory congestive heart failure due to secondary MR and demonstrated a significant reduction in the composite endpoint of all-cause mortality or hospitalization for heart failure. In addition, the trial also demonstrated significant improvements in quality of life and New York Heart Association functional class.
- The Mechanical Valves segment is expected to register the fastest revenue CAGR during the forecast period due to the rapid adoption of TAVI and the presence of a large number of key market players in this segment.
- The Mitral Valve Stenosis segment is expected to register the fastest revenue CAGR during the forecast period due to high prevalence of mitral valve stenosis, growing demands for minimally invasive procedures, and favorable reimbursement policies in the developed economies.
- The Hospital segment is expected to register the fastest revenue CAGR during the forecast period due to the increase in the number of hospitals adopting transcatheter mitral valve implantation procedures and the growing preference for this procedure over traditional surgical procedures.
- The European region is expected to register the largest revenue share in the global Transcatheter Mitral Valve Implantation market due to the increasing prevalence of cardiovascular diseases and the favorable reimbursement policies for TAVI procedures.
- The Asia Pacific is expected to register the fastest growth rate during the forecast period due to the factors such as the increasing prevalence of cardiovascular diseases, rising geriatric population, and improving healthcare infrastructure in this region.
- Key market players profiled for this industry analysis include Abbott Laboratories, HLT Medical, Neovasc, Edward Lifesciences, Biotronik Private Limited, LivaNova, Colibri Heart Valve, Medtronic, NeoChord, MValve Technologies, Transcatheter Technologies GmbH and Venus Medtech among other companies.
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/transcatheter-mitral-valve-implantation-market
For the purpose of this study, Emergen Research have segmented Transcatheter Mitral Valve Implantation Market on the basis of product, application, end use and region:
Product Outlook (Revenue in Million USD; 2017–2027)
- Mechanical Valves
- Bioprosthetic Tissue (Biological) Valves
Application Outlook (Revenue in Million USD; 2017–2027)
- Mitral Valve Stenosis
- Mitral Valve Prolapse
- Mitral Valve Regurgitation
End Use Outlook (Revenue in Million USD; 2017–2027)
- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers
- Other
Regional Outlook (Revenue in Million USD; 2017–2027)
- North America
- US.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/54
Explore More Reports Emergen Research:
High-performance Liquid Chromatography (HPLC) Market
Mass Notification Systems Market
Flow Imaging Microscopy Market
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Emergen Research Media Citations: https://www.emergenresearch.com/media-citations
Visit for More Insights: https://www.emergenresearch.com/insights
Explore Our Custom Intelligence services | Growth Consulting Services
Press Release Available @ https://www.emergenresearch.com/press-release/global-transcatheter-mitral-valve-implantation-market